Morris Shannon 4

What Happened

• Morris Shannon, Chief Medical Officer of Erasca, was granted a derivative equity award covering 625,000 shares on 2026-01-29. The grant is reported as a derivative acquisition with a reported acquisition amount of $0 on the Form 4 filed 2026-01-30. This was an award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-29; Form 4 filed: 2026-01-30 (timely filing).
• Reported transaction: Grant/Award (derivative) of 625,000 shares; reported price $0.00.
• Shares owned after transaction: Not disclosed in the Form 4.
• Vesting footnote: 1/48th of the shares subject to the option vest monthly on the 29th (or last day of February) starting February 2026, subject to continuous service (i.e., a 4‑year monthly vesting schedule).
• No indication in this filing of any immediate sale or exercise; future exercises/sales would be reported separately.

Context

• This appears to be an option-style equity award that vests over four years (monthly). It requires continued service to vest and does not represent an immediate cash purchase or sale by the insider.
• For retail investors: equity awards to executives are common retention/incentive tools; they are informational but do not by themselves indicate insider buying or selling intent. Separate Form 4s will disclose any later exercises or sales.